跳至主要内容
临床试验/EUCTR2015-003712-20-GB
EUCTR2015-003712-20-GB进行中(未招募)1 期

A randomised, double blind, double-dummy, placebo controlled trial of inhaled treatment to establish the mechanisms of prematurity-associated airway obstruction and inflammation. - RHINO: Respiratory Health Outcomes in Neonates

Cardiff University0 个研究点目标入组 7,000 人开始时间: 2019年11月13日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
7,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1)Children aged 7-12 at the time of screening
  • 2)Born at a gestational age =34 weeks (NB. sufficient numbers of term-born participants to enroll n=100 controls will also be invited)
  • 3)Resident in the south Wales area whom, in the opinion of the Investigator, are possible to follow up
  • 4)Fully informed proxy consent from parents/guardians and assent from child where possible
  • 1)As part 1
  • 2)Preterm-born children found during part 1 to have FEV1 =85% predicted
  • NB. Approximately N=100 preterm-born and N=100 term-born controls with %FEV1 >85% predicted will also be invited to Part 2 visit 1
  • 1)Preterm-born children found to have FEV1 =85% at baseline laboratory visit (part 2, visit 1) who participated in the treatment trial
  • 2)Willing to travel to the University of Sheffield Academic Unit of Radiology, Royal Hallamshire Hospital
  • NB. Approximately n=20 preterm-born and n=20 term-born controls (all with normal lung function) will also be invited to Part 3
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 200
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1)Respiratory tract infection within the last three 3 weeks (will be re-invited at a later date)
  • 2)Congenital abnormalities
  • 3)In the opinion of the Investigator:
  • severe cardiopulmonary defects, or
  • neuromuscular disease, or
  • severe neurodevelopmental impairment
  • Which prohibit the possibility of compliance with the study protocol
  • 1)As part 1
  • 2)Known hypersensitivity to salmeterol and/or fluticasone
  • 1)Surgery of any type in the previous 2 months
  • 2)Previous brain surgery involving placement of clips or shunts
  • 3)Eye injuries resulting from metal fragments
  • 4)Presence of any metal implants including pacemakers
  • 5)Possibility to be or known to be pregnant

研究者

相似试验

进行中(未招募)
不适用
A clinical study to look at the safety, effectiveness and how COPD patients tolerate a new compound CHF6001 which will be inhaled daily for 28 days compared with existing treatment and placeboThe participants of this study have chronic obstructive pulmonary disease (COPD).
EUCTR2012-001005-25-GBChiesi Farmaceutici S.p.A.65
已完成
3 期
A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids (FFA115285)10038716bronchial asthmaasthma
NL-OMON37429GlaxoSmithKline20
进行中(未招募)
不适用
A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.Asthma
EUCTR2010-020144-34-DEGlaxoSmithKline Research & Development Ltd330
进行中(未招募)
不适用
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type PsoriasisModerate to severe chronic plaque-type psoriasisMedDRA version: 13.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2010-022228-66-ISovartis Pharma AG1,264
进行中(未招募)
1 期
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type Psoriasis
EUCTR2010-022228-66-GBovartis Pharma AG1,306